Salesforce.com to B...
Health Care: Drugs
Exelixis Inc. (EXEL: NASDAQ)
$4.52 0.04 | 1.01%
06/04/12 - 12:30 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:7.02
Price Earnings Comparisons:
| EXEL | Sector Avg. | S&P 500 |
|---|---|---|
| 7.02 | 7.70 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -18.49 | -61.52 | -16.58 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 56.50 | 1.46 | 0.35 |
| Net Income | -1.46 | 0.00 | |
| EPS | -1.39 | 0.00 |
Earnings for EXEL:
| EBITDA | 106.49M |
| REVENUE | 289.64M |
Average Earnings Estimates
| Qtr (06/12) | Qtr (09/12) | FY (12/12) | FY (12/13) | |
|---|---|---|---|---|
| Average Estimate | $-0.28 | $-0.30 | $-1.07 | $-1.17 |
| Number of Analysts | 7 | 7 | 8 | 8 |
| High Estimate | $-0.24 | $-0.21 | $-0.88 | $-0.85 |
| Low Estimate | $-0.36 | $-0.35 | $-1.22 | $-1.49 |
| Prior Year | $-0.16 | $0.60 | $0.64 | $-1.07 |
| Growth Rate (Year over Year) | -75.00% | -150.24% | -267.19% | -9.00% |
Portfolios with EXEL
- Portfolio NameUser Type
- Contributor10 Stocks That Could Rise i...
- Contributor10 Biotech Stocks Loved and...
- Contributor10 Biotech Trades for Secon...
- UserMy Portfolio
- ContributorCancer Drug Stocks to Trade...
- Userbarry216 Portfolio 1
- UserSUPRATRADE HOT STOCKS (BUY ...
- UserASCO 2010
- UserBartwaldon Portfolio 1
- UserPART 3 JPMorgan 28th Annual...
Latest EXEL Headlines from TheStreet
- ASCO 2012 Live Blog -- Sunday 06.03.12 | 07:06 am
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- Exelixis' Management Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript) 05.17.12 | 06:05 pm
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Exelixis' Management Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript) 05.09.12 | 08:05 pm
- Friday's Top 10 Articles, Videos on TheStreet 05.04.12 | 01:05 pm
- Biotech Stock Mailbag: Exelixis, Protalix, Arena 05.04.12 | 07:05 am
- Exelixis's CEO Discusses Q1 2012 Results - Earnings Call Transcript 05.03.12 | 10:05 pm
- 10 Stocks That Could Rise in Market Decline 04.10.12 | 07:04 am
Press Releases for EXEL
- Cabozantinib Meets Primary Endpoint Of Progression Free Survival In Phase 3 Pivotal Trial In Medullary Thyroid Cancer - Business Wire 06.04.12 | 12:06 pm
- Cabozantinib Demonstrates Evidence Of Anti-Tumor Effects In Heavily Pretreated Patients With Hepatocellular Carcinoma - Business Wire 06.02.12 | 06:06 pm
- Cabozantinib Demonstrates Encouraging Activity In Patients With Heavily Pretreated Metastatic Renal Cell Carcinoma - Business Wire 06.02.12 | 05:06 pm
- Exelixis Announces June 6th Webcast Of Presentation At The Goldman Sachs 33rd Annual Global Healthcare Conference - Business Wire 05.31.12 | 05:05 pm
- Exelixis Initiates COMET-1 Pivotal Trial Focused On Overall Survival In Men With Advanced Prostate Cancer - Business Wire 05.30.12 | 06:05 am
- Exelixis Completes Submission Of New Drug Application For Cabozantinib For The Treatment Of Medullary Thyroid Cancer - Business Wire 05.30.12 | 06:05 am
- Reminder: Exelixis Announces Data Presentations, Webcast Of Investor Briefing In Conjunction With 2012 ASCO Annual Meeting - Business Wire 05.16.12 | 06:05 am
- Exelixis Expands The Cabozantinib Development Program Through NCI-CTEP Collaboration - Business Wire 05.03.12 | 06:05 am
- Exelixis Announces May 8th Webcast Of Presentation At The Deutsche Bank Securities 37th Annual Health Care Conference - Business Wire 05.02.12 | 04:05 pm
- Exelixis Announces May 3rd Webcast Of First Quarter 2012 Financial Results Conference Call - Business Wire 04.19.12 | 04:04 pm
Partner Headlines for EXEL
- Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily Pretreated Patients with Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- UPDATE: Piper Jaffray Downgrades Exelixis to Neutral - Benzinga 11.01.11 | 09:11 am
- Notable Put Options Activity in Exelixis - Benzinga 10.28.11 | 01:10 pm
- 3 Biotech Takeover/LBO Targets With Bullish Short Trends - Seeking Alpha 10.26.11 | 09:10 am
- 7 Possible Biotech Takeover Targets - Seeking Alpha 09.18.11 | 08:09 am
- Biotech Gem Exelixis Is Compelling Only for the Long Term - Seeking Alpha 08.19.11 | 05:08 pm
- 5 Biotech Takeover / LBO Targets With Bullish Short Trends - Seeking Alpha 07.15.11 | 07:07 pm
- Exelixis extends timeline for thyroid cancer data - Reuters 07.06.11 | 04:07 pm
